TITLE

CD4+ Count—Guided Interruption of Antiretroviral Treatment

PUB. DATE
November 2006
SOURCE
New England Journal of Medicine;11/30/2006, Vol. 355 Issue 22, p2283
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV). Methods: We randomly assigned persons infected with HIV who had a CD4+ cell count of more than 350 per cubic millimeter to the continuous use of antiretroviral therapy (the viral suppression group) or the episodic use of antiretroviral therapy (the drug conservation group). Episodic use involved the deferral of therapy until the CD4+ count decreased to less than 250 per cubic millimeter and then the use of therapy until the CD4+ count increased to more than 350 per cubic millimeter. The primary end point was the development of an opportunistic disease or death from any cause. An important secondary end point was major cardiovascular, renal, or hepatic disease. Results: A total of 5472 participants (2720 assigned to drug conservation and 2752 to viral suppression) were followed for an average of 16 months before the protocol was modified for the drug conservation group. At baseline, the median and nadir CD4+ counts were 597 per cubic millimeter and 250 per cubic millimeter, respectively, and 71.7% of participants had plasma HIV RNA levels of 400 copies or less per milliliter. Opportunistic disease or death from any cause occurred in 120 participants (3.3 events per 100 person-years) in the drug conservation group and 47 participants (1.3 per 100 person-years) in the viral suppression group (hazard ratio for the drug conservation group vs. the viral suppression group, 2.6; 95% confidence interval [CI], 1.9 to 3.7; P<0.001). Hazard ratios for death from any cause and for major cardiovascular, renal, and hepatic disease were 1.8 (95% CI, 1.2 to 2.9; P=0.007) and 1.7 (95% CI, 1.1 to 2.5; P=0.009), respectively. Adjustment for the latest CD4+ count and HIV RNA level (as time-updated covariates) reduced the hazard ratio for the primary end point from 2.6 to 1.5 (95% CI, 1.0 to 2.1). Conclusions: Episodic antiretroviral therapy guided by the CD4+ count, as used in our study, significantly increased the risk of opportunistic disease or death from any cause, as compared with continuous antiretroviral therapy, largely as a consequence of lowering the CD4+ cell count and increasing the viral load. Episodic antiretroviral therapy does not reduce the risk of adverse events that have been associated with antiretroviral therapy. (ClinicalTrials.gov number, NCT00027352.) N Engl J Med 2006;355:2283-96.
ACCESSION #
24930053

 

Related Articles

  • Retrospective Analysis of Suspending HAART in Selected Patients with Controlled HIV Replication. Jacobs, Benjamin; Neil, Nancy; Aboulafia, David M. // AIDS Patient Care & STDs;Jul2005, Vol. 19 Issue 7, p429 

    We sought to determine the consequences of stopping highly active antiretroviral therapy (HAART) in a group of 41 HIV-infected individuals with undetectable HIV viral loads and CD4+ counts greater than 500 cells per microliter for 6 months or more. Clinical and laboratory parameters were...

  • HIV: Saving patients we used to lose. O'Connor, Patrick G. // Cortlandt Forum;8/25/2004, Vol. 17 Issue 8, p15 

    Discusses the utilization of antiretroviral therapy in treating HIV. Need of the therapy to be considered in HIV and symptomatic patients with CD4 cell counts of 201-350; Initial regimens to be used in the initial treatment of HIV; Right time for drug regimens to be changed.

  • A Comparison of Immediate with Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults with CD4 Cell Counts of 500 or More per Cubic Millimeter. Volberding, Paul A.; Lagakos, Stephen W.; Grimes, Janet M.; Stein, Daniel S.; Rooney, James; Meng, Tze-Chiang; Fischl, Margaret A.; Collier, Ann C.; Phair, John P.; Hirsch, Martin S.; Hardy, W. David; Balfour, Henry H.; Reichman, Richard C. // New England Journal of Medicine;8/17/95, Vol. 333 Issue 7, p401 

    Background: The clinical benefits of zidovudine remain unproved in patients with asymptomatic human immunodeficiency virus (HIV) infection when CD4 cell counts exceed 500 per cubic millimeter. We compared zidovudine therapy given immediately with deferred therapy in such subjects. Methods:...

  • A Comparison of Immediate with Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults with CD4 Cell Counts of 500 or More per Cubic Millimeter. Volberding, Paul A.; Lagakos, Stephen W.; Grimes, Janet M.; Stein, Daniel S.; Rooney, James; Meng, Tze-Chiang; Fischl, Margaret A.; Collier, Ann C.; Phair, John P.; Hirsch, Martin S.; Hardy, W. David; Balfour, Henry H.; Reichman, Richard C. // New England Journal of Medicine;8/17/95, Vol. 333 Issue 7, p401 

    Background: The clinical benefits of zidovudine remain unproved in patients with asymptomatic human immunodeficiency virus (HIV) infection when CD4 cell counts exceed 500 per cubic millimeter. We compared zidovudine therapy given immediately with deferred therapy in such subjects. Methods:...

  • Can HCV affect the efficacy of anti-HIV treatment? Filippini, P.; Coppola, N.; Scolastico, C.; Liorre, G.; Nocera, R.; Sagnelli, E.; Piccinino, F. // Archives of Virology;May2000, Vol. 145 Issue 5, p937 

    Summary. To evaluate the impact of new antiretroviral combinations (HAART: Highly Active Anti Retroviral Therapy) on HCV replication and liver enzyme levels, we analysed the changes in HCV viremia and aminotransferase levels in HIV and HCV co-infected patients. Moreover, to evaluate the...

  • Behcet's disease with HIV infection: response to antiretroviral therapy. Mahajan, Vlkram K.; Sharma, Nand Lal; Sharma, Vikas C.; Sharma, Ramesh Chander; Sarin, Sandip; Mahajan, Vikram K // Indian Journal of Dermatology, Venereology & Leprology;Jul/Aug2005, Vol. 71 Issue 4, p276 

    The differential diagnosis of oral ulcerations in a patient with AIDS/HIV infection is often challenging to the clinician. While old diseases have appeared in a new garb, many new ones are also being recognized. The association of Behetaet's disease and AIDS/HIV infection has been recently...

  • Social self-value intervention for empowerment of HIV infected people using antiretroviral treatment: a randomized controlled trial. Bhatta, Dharma Nand; Liabsuetrakul, Tippawan // BMC Infectious Diseases;6/10/2016, Vol. 16, p1 

    Background: Prevention and antiretroviral therapy (ART) management for human immunodeficiency virus (HIV) infected people need to have long-term health care. An empowerment focused intervention is a procedure by which HIV infected people obtain combined possession of programs to...

  • Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. Negredo, Eugènia; Massanella, Marta; Puertas, Maria C.; Buzón, Maria J.; Puig, Jordi; Pérez-Alvárez, Núria; Pérez-Santiago, Josué; Bonjoch, Anna; Moltó, José; Jou, Antoni; Echeverría, Patricia; Llibre, Josep M.; Martínez-Picado, Javier; Clotet, Bonaventura; Blanco, Julià // Journal of Antimicrobial Chemotherapy (JAC);Oct2013, Vol. 68 Issue 10, p2358 

    Background Immune hyperactivation in immunodiscordant patients can induce residual HIV replication and limit CD4 T cell recovery. We assessed the impact of raltegravir intensification on CD4 T cell recovery and viral persistence. Methods We performed a randomized, controlled, pilot trial....

  • Performance of absolute CD4+ count in predicting co-infection with human T-lymphotropic virus type 1 in antiretroviral-naïve HIV-infected patients. Gudo, Jr., E. S.; Bhatt, N. B.; Augusto, O.; Sema, C.; Savino, W.; Ferreira, Jr., O. C.; Jani, I. V. // International Journal of STD & AIDS;Oct2012, Vol. 23 Issue 10, p717 

    Early identification of patients co-infected with HIV and human T-lymphotropic virus type 1 (HTLV-1) is essential to improve care, as CD4+ T-cell counts have been revealed to be an unreliable laboratory parameter to monitor HIV infection in co-infection. Unfortunately, HTLV-1 testing is not...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics